Last10K.com

Actinium Pharmaceuticals, Inc. (ATNM) SEC Filing 8-K Material Event for the period ending Tuesday, June 28, 2022

Actinium Pharmaceuticals, Inc.

HISTORY TOOLS
CIK: 1892322 Ticker: ATNM

View differences made from one to another to evaluate Actinium Pharmaceuticals, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Actinium Pharmaceuticals, Inc..

Continue

Assess how Actinium Pharmaceuticals, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Actinium Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 8-K Corporate News

Cover

Material Contracts, Statements, Certifications & more

Actinium Pharmaceuticals, Inc. provided additional information to their SEC Filing as exhibits

Exhibit 1.1: Amended And Restated Capital On Demandtm Sales Agreement By And Between Actinium
Ticker: ATNM
CIK: 1388320
Form Type: 8-K Corporate News
Accession Number: 0001213900-22-035693
Submitted to the SEC: Wed Jun 29 2022 8:00:23 AM EST
Accepted by the SEC: Wed Jun 29 2022
Period: Tuesday, June 28, 2022
Industry: Pharmaceutical Preparations
Events:
  1. Financial Exhibit
  2. New Agreement

External Resources:
Stock Quote
Social Media
SEC.gov

Bookmark the Permalink:
https://last10k.com/sec-filings/atnm/0001213900-22-035693.htm